| Features |
| • | Broad spectrum bactericidal |
| • | Irreversible inhibition of bacterial Protein Synthesis |
| • | Resists degradation by most of the bacterial enzymes that inactivate other Aminoglycosides |
| • | Only agent to treat serious Gram – ve infections especially caused by Pseudomonas spp |
| • | Most effective and least toxic |
| • | Antibiotic of choice to reduce the severity of bacteremia and other bacterial complications |
| • | Concentration dependent bactericidal drug and exhibits Post – Antibiotic effect (PAE) |
| • | Synergism with ß – lactam antibiotics |
| • | Rapid absorption & onset of action |
| • | Low Plasma Protein binding |
| • | High Bioavailability (90 - 100 %) |
| • | High levels in bronchial secretions |
| • | Highly active in alkaline pH |
| • | Elimination by renal excretion (t1/2 - 2 hrs; Vd - 0.15 - 0.3 L/kg) |
| • | No hepatic metabolism and so very suitable in systemically ill and premature neonates with impaired hepatic function |
Composition |
| Each ml contains: |
| • | Amikacin Sulphate IP equivalent to Amikacin 250 mg |
| • | Methyl paraben IP 0.18 % w/v |
| • | Propyl paraben IP 0.025 % w/v |
| • | Water for Injection IP q.s |
Indications |
| • | Wound infections |
| • | Cystitis, Pyelonephritis & other Urinary tract infections |
| • | Respiratory Tract infections |
| • | Arthritis & Osteomyelitis |
| • | Pathogenic E. coli infections |
